Through its activation of the p27Kip1 and p53–p21WAF1/Cip1 pathways, KPT-330 demonstrates its capability to induce cell death and halt cell proliferation in CTCL cells. Here, TP53 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.